Structure Therapeutics
GPCR
26.68
-0.79
-2.88%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
26.68
-0.79
-2.88%
Live - 5344 symbols - heartbeat 433s ago
· 2026-10-08 06:41
Pre-market
26.46
-0.82%
After-hours
27.00
+1.20%
Overnight
26.78
+0.37%
- Market cap
- 1.90B
- P/E (TTM)i
- -8.81
- P/Bi
- 1.40
- EPSi
- -2.40
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on GPCR?
Anonymous reader poll. Unscientific, not investment advice.
About Structure Therapeutics
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
- Founded
- 2016
- CEO
- Professor Raymond C. Stevens, PhD
- Employees
- 220
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- structuretx.com
Company profile
- Exchange
- US
- Symbol
- GPCR
- Market-cap rank
- #2815
- Listing date
- 2023-02-03
- Market cap
- 1.90B
- Float cap
- 1.48B
- Shares out
- 71.31M
- Float shares
- 55.46M
Sectors & themes
Quote time 2026-10-08 06:41:41 · For reference only, not investment advice and not tailored to your situation.